<SEC-DOCUMENT>0000899243-23-017270.txt : 20230707
<SEC-HEADER>0000899243-23-017270.hdr.sgml : 20230707
<ACCEPTANCE-DATETIME>20230707163013
ACCESSION NUMBER:		0000899243-23-017270
CONFORMED SUBMISSION TYPE:	3
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20230628
FILED AS OF DATE:		20230707
DATE AS OF CHANGE:		20230707

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			ELI LILLY & Co
		CENTRAL INDEX KEY:			0000059478
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		STATE OF INCORPORATION:			IN
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		3
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39746
		FILM NUMBER:		231077101

	BUSINESS ADDRESS:	
		STREET 1:		LILLY CORPORATE CTR
		STREET 2:		DROP CODE 1094
		CITY:			INDIANAPOLIS
		STATE:			IN
		ZIP:			46285
		BUSINESS PHONE:		3172762000

	MAIL ADDRESS:	
		STREET 1:		LILLY CORPORATE CENTER
		STREET 2:		DROP CODE 1094
		CITY:			INDIANAPOLIS
		STATE:			IN
		ZIP:			46285

	FORMER NAME:	
		FORMER CONFORMED NAME:	LILLY ELI & CO
		DATE OF NAME CHANGE:	19941024

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Shenandoah Acquisition Corp
		CENTRAL INDEX KEY:			0001983165
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		3
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39746
		FILM NUMBER:		231077100

	BUSINESS ADDRESS:	
		STREET 1:		LILLY CORPORATE CENTER
		STREET 2:		893 DELAWARE STREET
		CITY:			INDIANAPOLIS
		STATE:			IN
		ZIP:			46285
		BUSINESS PHONE:		317-276-2000

	MAIL ADDRESS:	
		STREET 1:		LILLY CORPORATE CENTER
		STREET 2:		893 DELAWARE STREET
		CITY:			INDIANAPOLIS
		STATE:			IN
		ZIP:			46285

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Sigilon Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001821323
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				474005543
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		100 BINNEY STREET
		STREET 2:		STE 600
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		617-336-7540

	MAIL ADDRESS:	
		STREET 1:		100 BINNEY STREET
		STREET 2:		STE 600
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
</SEC-HEADER>
<DOCUMENT>
<TYPE>3
<SEQUENCE>1
<FILENAME>doc3.xml
<DESCRIPTION>FORM 3 SUBMISSION
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0206</schemaVersion>

    <documentType>3</documentType>

    <periodOfReport>2023-06-28</periodOfReport>

    <noSecuritiesOwned>0</noSecuritiesOwned>

    <issuer>
        <issuerCik>0001821323</issuerCik>
        <issuerName>Sigilon Therapeutics, Inc.</issuerName>
        <issuerTradingSymbol>SGTX</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0000059478</rptOwnerCik>
            <rptOwnerName>ELI LILLY &amp; Co</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>LILLY CORPORATE CENTER</rptOwnerStreet1>
            <rptOwnerStreet2></rptOwnerStreet2>
            <rptOwnerCity>INDIANAPOLIS</rptOwnerCity>
            <rptOwnerState>IN</rptOwnerState>
            <rptOwnerZipCode>46285</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>0</isDirector>
            <isOfficer>0</isOfficer>
            <isTenPercentOwner>1</isTenPercentOwner>
            <isOther>0</isOther>
        </reportingOwnerRelationship>
    </reportingOwner>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001983165</rptOwnerCik>
            <rptOwnerName>Shenandoah Acquisition Corp</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>LILLY CORPORATE CENTER</rptOwnerStreet1>
            <rptOwnerStreet2></rptOwnerStreet2>
            <rptOwnerCity>INDIANAPOLIS</rptOwnerCity>
            <rptOwnerState>IN</rptOwnerState>
            <rptOwnerZipCode>46285</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>0</isDirector>
            <isOfficer>0</isOfficer>
            <isTenPercentOwner>1</isTenPercentOwner>
            <isOther>0</isOther>
        </reportingOwnerRelationship>
    </reportingOwner>

    <nonDerivativeTable>
        <nonDerivativeHolding>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>211110</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeHolding>
    </nonDerivativeTable>

    <footnotes></footnotes>

    <remarks>Eli Lilly and Company (&quot;Lilly&quot;) beneficially owns and has a pecuniary interest in 211,110 shares of the Issuer's common stock (as adjusted for the 1-for-13 reverse stock split of the Issuer, effective as of May 22, 2023, as reported by the Issuer in its Current Report on Form 8-K, filed on May 22, 2023) (the &quot;Owned Shares&quot;).  In addition, in connection with the Agreement and Plan of Merger, dated as of June 28, 2023, among the reporting persons and the Issuer, the reporting persons entered into tender and support agreements, each dated as of June 28, 2023 (collectively, the &quot;Tender and Support Agreements&quot;), with (i) Flagship Ventures Fund V LP and (ii) Flagship Pioneering Special Opportunities Fund II LP (collectively, the &quot;Parties&quot;), pursuant to which each of the Parties agreed to grant certain voting rights to Lilly with respect to the shares of Issuer's common stock held by each such Party (collectively, the &quot;Support Shares&quot;). As a result of the Tender and Support Agreements and in the case of Lilly, the Owned Shares, each of the reporting persons may be deemed to have acquired beneficial ownership in excess of 10% of the Issuer's issued and outstanding common stock for the purpose of determining each reporting person's status as a ten percent owner thereof. However, neither of the reporting persons has a pecuniary interest in the Support Shares and each expressly disclaims beneficial ownership thereof. The filing of this Form 3 shall not be deemed an admission of beneficial ownership of the Support Shares for the purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. In addition, Shenandoah Acquisition Corporation disclaims beneficial ownership in the Owned Shares.</remarks>

    <ownerSignature>
        <signatureName>/s/ Anat Ashkenazi, Executive Vice President and Chief Financial Officer, on behalf of Eli Lilly and Company</signatureName>
        <signatureDate>2023-07-07</signatureDate>
    </ownerSignature>

    <ownerSignature>
        <signatureName>/s/ Philip L. Johnson, President, on behalf of Shenandoah Acquisition Corporation</signatureName>
        <signatureDate>2023-07-07</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
